Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06954584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

StatusRecruiting
PhasePhase 3
Started2025-05-27
View on ClinicalTrials.gov ↗

Amendment history

2025-06-17
Not Yet Recruiting→Recruiting Study Status, Oversight, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05-01→confirmed 2025-05-27
Study sites1→2
2025-04-24
Original filing
Tongji Hospital
197 trials monitored
See 2 trials at risk
Ovarian Cancer
1,239 trials monitored
See 74 trials at risk
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP inhibitors . In vitro evidence suggests that low-carbohydrate culture conditions may restore PARP inhibitor sensitivity in HRD-negative tumor cells. This study aims to validate the survival benefits of fluzoparib combined with bevacizumab in HRD-positive ovarian cancer patients during first-line maintenance therapy and explore the efficacy of fluzoparib combined with a dietary intervention in HRD-negative populations.
Trial Details
NCT Number NCT06954584
Lead Sponsor Tongji Hospital
Conditions Ovarian Cancer
Enrollment 424 participants
Start Date 2025-05-27
Primary Completion 2030-05-01 (estimated)
Study Completion 2032-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-24